24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Teva Pharmaceutical Industries
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:28
The PC productivity paradox, again
21:03
Nvidia and Microsoft push Washington to protect open AI models
20:36
OpenAI took days to realize its own AI agent breached Hugging Face
20:10
From Mobileye to doubleAI and beyond, Amnon Shashua is preparing for his next act
More stories
Buzz
Most popular
Daily
Weekly
1
OPPO’s thinnest foldable yet shows the promise, and limits, of the category
2
Anduril targets $100 billion valuation in new funding talks
3
ServiceNow's latest earnings show why it paid $7.75 billion for Armis
4
From Iron Dome at sea to AI-powered warfare Israel exports the lessons of October 7
5
Israel’s Iron Dome and Arrow makers head toward IPOs, but the listing battle is far from over
More news
Teva Pharmaceutical Industries
6 stories about Teva Pharmaceutical Industries
Troubled Drugmaker Teva to Axe over 4,000 Jobs
23.11.17
|
Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
New Teva CEO Kåre Schultz to Relocate to Israel
17.10.17
|
Golan Hazani
Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
The Ten Challenges Facing Teva's New CEO
12.09.17
|
Sophie Shulman
Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board
Teva Sells IUD Business for $1.1 Billion
12.09.17
|
Lilach Baumer
Going forward, the company will focus on central nervous system and respiratory treatments, shedding its Women's Health and Oncology and Pain businesses
Teva Appoints Lundbeck's Schultz as CEO
11.09.17
|
Dror Reich and Micky Grunfeld
The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated
Previous Articles
